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ABSTRACT
Objectives To identify factors that predict repeat
admissiontohospitalforadversedrugreactions(ADRs)in
older adults.
Design Population based retrospective cohort study.
Setting All public and private hospitals in Western
Australia.
Participants 28548 patients aged ≥60 years with an
admissionforanADRduring1980-2000followedforthree
years using the Western Australian data linkage system.
Results 5056 (17.7%) patients had a repeat admission for
anADR.RepeatADRswereassociatedwithsex(hazardratio
1.08, 95% confidence interval 1.02 to 1.15, for men), first
admissionin1995-9(2.34,2.00to2.73),lengthofhospital
stay (1.11, 1.05 to 1.18, for stays ≥14 days), and Charlson
comorbidityindex(1.71,1.46to1.99,forscore≥7);60%of
comorbidities were recorded and taken into account in
analysis.Incontrast,advancingagehadnoeffectonrepeat
ADRs. Comorbid congestive cardiac failure (1.56, 1.43 to
1.71), peripheral vascular disease (1.27, 1.09 to 1.48),
chronic pulmonary disease (1.61, 1.45 to 1.79),
rheumatological disease (1.65, 1.41 to 1.92), mild liver
disease (1.48, 1.05 to 2.07), moderate to severe liver
disease(1.85,1.18to2.92),moderatediabetes(1.18,1.07
to1.30),diabeteswithchroniccomplications(1.91,1.65to
2.22), renal disease (1.93, 1.71 to 2.17), any malignancy
including lymphoma and leukaemia (1.87, 1.68 to 2.09),
and metastatic solid tumours (2.25, 1.92 to 2.64) were
strong predictive factors. Comorbidities requiring
continuing care predicted a reduced likelihood of repeat
hospital admissions for ADRs (cerebrovascular disease
0.85,0.73to0.98;dementia0.62,0.49to0.78;paraplegia
0.73, 0.59 to 0.89).
ConclusionsComorbidity,butnotadvancingage,predicts
repeat admission for ADRs in older adults, especially
those with comorbidities often managed in the
community. Awareness of these predictors can help
clinicians to identify which older adults are at greater risk
of admission for ADRs and, therefore, who might benefit
from closer monitoring.
INTRODUCTION
Adverse drug reactions (ADRs) are a major public
health problem in older populations.
1-3 In Western
countries, ADRs cause 3-6% of all hospital
admissions
1-3 and are responsible for about 5-10% of
inpatient costs.
4-6 We have previously reported that
repeat ADRs resulting in either hospital admission or
extended hospital stay increased at a greater rate than
first time ADRs in older adults from 1980-2003.
Furthermore, in Western Australia by 2003 over 30%
of all ADRs were repeat ADRs.
7
Despite concerns that ADRs represent an important
medicalprobleminolderpeople,thepredictivefactors
are still poorly understood. Older patients are vulner-
able to ADRs because of the multiple drugs that they
receivetomanagechronicdiseasesandalsobecauseof
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pharmacodynamics.
89 Risk factors reported to be
independently associated with ADRs have included
advancing age, sex, comorbidity, multiple drug regi-
mens,inappropriate use ofmedication,alcohol intake,
poor cognitive function, and depression.
410-15 There is
currently no consensus on which factors have the
greatest impact.
Weconductedaretrospectivecohortstudybasedon
a state-wide population of patients to investigate
whether or not comorbid conditions, age and other
demographicfactors,anddrugcategoryareassociated
with a repeat admission for ADRs in people aged ≥60.
METHODS
Study setting and population
We used administrative data from all public and
private hospitals in Western Australia, a state with a
population of 2.09 million in 2007.
16 The study
population consisted of all residents aged ≥60 with a
hospital admission related to an ADR identified
through the data linkage system. This system links
state-wide administrative health data at the individual
level using probabilistic matching of patients’ names
and other identifiers with clerical review of doubtful
matches.It includeslinksbetweenseven coredatasets,
ofwhichthestatutorydeathregistryfrom1969andthe
hospital morbidity data system (HMDS) from 1970
form the main parts.
17 We used extracts of linked
hospital morbidity records and death records, with
encryptiontoprotecttheidentityofindividualpatients.
The data were extracted in February 2005.
The hospital morbidity data system contained
information on encrypted patient identification and
episode number; age, sex, indigenous status, and
postcode; date of admission and date of separation
(that is, transfer, discharge, or inpatient death); inter-
national classification of diseases (ICD) codes for the
maindiagnosisandupto19additionaldiagnosesforup
to four external causes (E codes), and for the main
procedure and up to 10 additional procedures; type of
hospital attended (public, private, other), admission
type (emergency or elective), and payment classifica-
tion. We used ICD-9 for 1980-7,
18 ICD-9-CM for
1988-June 1999,
19 and ICD-10-AM from July 1999
onwards.
20 Data from the death records included
encrypted patient identification, age, sex, indigenous
status, primary cause of death, date of death, and
postcode. We extracted linked hospital and death
records for all patients aged ≥60 with an admission for
ADR in 1980-2003 in Western Australia. In an
assessmentof the technicalperformance of the linkage
system in finding true matches between records, both
the proportion of invalid links (false positives) and of
missed links (false negatives) was estimated to be
0.11%.
17
Definition of ADR and identification of patients
We included all ADRs that resulted in hospital
admission or that occurred while patients were in
hospital and extended the length of hospital stay. An
ADReventwasdefinedasanyhospitalseparationwith
an ICD E code indicating that either the admission or
extended hospital stay was because of the adverse
effectsofdrugs,medicines,andbiologicalsubstancesin
therapeutic use: E930–E949 (ICD-9 and ICD-9-CM)
or Y40–Y59 (ICD-10-AM). The codes included any
adverse effect caused by correct use of drugs,
medicines, or biological substances properly adminis-
tered in therapeutic or prophylactic doses, excluding
errors in the technique of administration of drugs,
intentionaland unintentional overdose,and abuseof a
drug.Thus,ourdefinitionofADRswasconsistentwith
the more recent and clearer version: “An appreciably
harmful or unpleasant reaction, resulting from an
intervention related to the use of a medicinal product,
which predicts hazard from future administration and
warrantspreventionorspecifictreatment,oralteration
ofthedosageregimen,orwithdrawaloftheproduct.”
21
Table 1 |Drug categories (from ICD external cause codes) responsible for admission for first
time adverse drug reaction (ADR) in patients aged ≥60, Western Australia, 1980-2000
Drugcategory(asdefinedinICD-10-AM) ICD-9/ICD-9-CM ICD-10-AM No (%) of patients
Systemic antibiotics* E930 Y40 2672 (9.4)
Other systemic anti-infectives/
antiparasitics
E931 Y41 430 (1.5)
Hormones (including synthetics and
antagonists)
E932 Y42 2174 (7.6)
Primarily systemic agents E933 Y43 2122 (7.4)
Agents primarily affecting blood
constituents
E934 Y44 2432 (8.5)
Analgesics/antipyretics/anti-
inflammatory drugs
E935 Y45 4694 (16.4)
Antiepileptics/antiparkinsonian drugs E936 Y46 1121 (3.9)
Sedatives, hypnotics, antianxiety drugs E937 Y47 406 (1.4)
Anaesthetics and therapeutic gases E938 Y48 414 (1.5)
Psychotropic drugs† E939 Y49 1534 (5.4)
Central nervous system stimulants E940 Y50 18 (0.1)
Drugs primarily affecting autonomic
nervous system‡
E941 Y51 476 (1.7)
Agents primarily affecting cardiovascular
system
E942 Y52 5576 (19.5)
Agentsprimarilyaffectinggastrointestinal
system
E943 Y53 252 (0.9)
Agentsaffectingwaterbalance/minerals/
uric acid§
E944 Y54 2024 (7.1)
Agents affecting muscles/respiratory
system
E945 Y55 563 (2.0)
Topical agents affecting skin, eyes, ENT,
dental
E946 Y56 577 (2.0)
Other and unspecified drugs and
medicines
E947 Y57 982 (3.4)
Bacterial vaccines E948 Y58 16 (0.1)
Other and unspecified vaccines/
biologicals
E949 Y59 65 (0.2)
Total 28 548 (100.0)
ADR=adverse drug reaction; ICD=International Classification of Diseases; ENT=ear, nose, throat.
*Excludes antineoplastic antibiotics (E930.7) from ICD-9/ICD-9-CM (were added to primarily systemic agents,
which include antineoplastics).
†Excludes benzodiazepines (E939.4) from ICD-9/ICD-9-CM (were added to group sedatives, hypnotics,
antianxiety drugs, which includes benzodiazepines in ICD-10).
‡Excludes sympatholytics (E941.3) from ICD-9/ICD-9-CM (were added to agents primarily affecting
cardiovascular system, which include these in ICD-10).
§Excludes theophylline (E944.1) from ICD-9/ICD-9-CM (was added to agents affecting muscles/respiratory
system, which includes antiasthmatics).
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continuous treatment for an ADR in one or more
hospitals,asapersonmighthavebeentransferredfrom
one hospital to another before they were discharged.
We checkedall recordsfor transfers betweenhospitals
and,wheretheyexisted,combinedtheadmissionsinto
a single “episode” for analysis.
To ensure correct identification of first time ADRs,
we initially examined all admissions of the patients
dating back to 1970. We included 803732 hospital
separations and audited these records to ensure that
each patient met the selection criteria. We excluded
people who were not residents of Western Australia
and those with hospital episodes unrelated to ADRs.
Therewere37296patientswholivedandweretreated
in Western Australia and had at least one admission
episode for an ADR. Each patient’s first ADR record
was identified, thereby distinguishing first time from
repeat episodes. We included 28548 patients with a
first time ADR in 1980-2000 as a cohort and followed
themupforthreeyears.Thefigureshowstheprocessof
selecting patients for the study.
Follow-up and outcome measurements
The length of follow-up was the time in days from
hospitalseparationforthefirsttimeADRepisode(time
zero) to the date of a second separate admission for an
ADR or, in the absence of a repeat event within three
years, to the date of the third anniversary from time
zero or date of death if within three years (censored).
We identified the drugs responsible for first time
ADRsfromtheEcodesonthehospitalmorbiditydata
system.Inthe3.9%ofallinstanceswhenmultipledrugs
werethoughttoberesponsibleforanADRweincluded
intheanalysisonlythedrugclinicallyconsideredtobe
primarily responsible. Drugs were grouped into 20
broad categories as defined in ICD-10-AM, with
closest possible equivalent specifications for ICD-9
and ICD-9-CM. Table 1 shows the distributions of
admissionsforfirsttimeADRsaccordingtothesedrug
categoriesanddetailsthemodificationsrequiredinthe
drugcategoriescausedby differencesbetweenICD-9/
ICD-9-CM and ICD-10-AM. Table 2 gives more
specific details of the top 30 drug groups most often
implicated in first time ADRs at the four digit E code
level (ICD-9/ICD-9-CM) and three digit Y code level
(ICD-10-AM), which accounted for more than 81% of
all episodes in the study.
Comorbidity was measured by using the Charlson
comorbidity index
22 conditions mentioned in the
hospital record for the first time ADR, coded to an
ICD-9, ICD-9-CM, or ICD-10-AM rubric that were
different from the principal index diagnosis. Nineteen
fieldsexistedwithinthehospitalmorbiditydatasystem
for recording comorbid conditions. The performance
of the linkage system in adjusting for comorbidty in
longitudinal research designs has been previously
demonstrated.
2324 We calculated the Charlson score
by adding scores assigned to each specific diagnosis,
which was generated using the Dartmouth-Manitoba
algorithms for ICD coded administrative data.
2526
Table 3 shows Charlson comorbid conditions (with
weights) present at the admission for first time ADR.
Weassignedasocioeconomicdisadvantagescorefor
each patient by transforming residential postcode into
numerical values of the index of relative socioeco-
nomic disadvantage compiled from the 1986, 1991,
1996, and 2001 Australian censuses and applied to
1980-8, 1989-93, 1994-8, and 1999-2003,
respectively.
27 The index was developed by the
Table 2 |Top 30 drug groups (ICD E codes) most often implicated in admission for first time
adverse drug reaction (ADR) in 28 548 patients aged ≥60, Western Australia, 1980-2000
Drug groups (as defined in ICD-10-AM) ICD-9/ICD-9-CM ICD-10-AM
No (%) of
patients
Systemic antibiotics:
Penicillins E930.0 Y40.0 881 (3.1)
Unspecified systemic antibiotics E930.9 Y40.9 569 (2.0)
Other systemic antibiotics E930.8 Y40.8 505 (1.8)
Cephalosporins and other β lactams E930.5 Y40.1 353 (1.2)
Hormones (including synthetics and antagonists):
Glucocorticoids and synthetics E932.0 Y42.0 1328 (4.7)
Insulins and oral antidiabetic drugs E932.3 Y42.3 416 (1.5)
Primarily systemic agents:
Antineoplastic/immunosuppressive drugs E933.1/E930.7 Y43.1-4 1980 (6.9)
Agents primarily affecting blood constituents:
Anticoagulants E934.2 Y44.2 1964 (6.9)
Thrombolytic drugs E934.4 Y44.5 247 (0.9)
Analgesics/antipyretics/anti-inflammatory drugs:
NSAIDs and antirheumatics E935.6 Y45.2-4 2026 (7.1)
Opioids and related analgesics E935.2 Y45.0 1388 (4.9)
Salicylates E935.3 Y45.1 442 (1.5)
4-aminophenol derivatives (such as paracetamol) E935.4 Y45.5 361 (1.3)
Antiepileptics and antiparkinsonian drugs:
Hydantoin derivatives E936.1 Y46.2 408 (1.4)
Antiparkinsonian drugs E936.4 Y46.7 359 (1.3)
Other and unspecified antiepileptics E936.3 Y46.6 302 (1.1)
Psychotropic drugs:
Antidepressants E939.0 Y49.0-2 596 (2.1)
Phenothiazine antipsychotics/neuroleptics E939.1 Y49.3 365 (1.3)
Agents primarily affecting cardiovascular system:
Cardiac stimulant glycosides/similar drugs E942.1 Y52.0 1702 (6.0)
Other antihypertensive drugs E942.6 Y52.5 1708 (6.0)
Other antidysrhythmic drugs E942.0 Y52.2 786 (2.8)
Coronary vasodilators E942.4 Y52.3 662 (2.3)
Peripheral vasodilators (ICD-9 sympatholytics) E941.3 Y52.7 269 (0.9)
Agents affecting water balance, mineral/uric acid metabolism:
Loop and other diuretics E944.4 Y54.4-5 1257 (4.4)
Benzothiadiazine derivatives E944.3 Y54.3 322 (1.1)
Uric acid metabolism drugs (such as colchicine) E944.7 Y54.8 242 (0.8)
Agents affecting muscles/respiratory system:
Antiasthmatics (including theophylline) E944.1/E945.7 Y55.6 472 (1.7)
Topical agents affecting skin, eyes, ENT, dental:
Local anti-infectives/anti-inflammatory drugs E946.0 Y56.0 435 (1.5)
Other and unspecified drugs and medicines:
Unspecified drug or medicines E947.9 Y57.9 555 (1.9)
Other drugs or medicines E947.8 Y57.8 354 (1.2)
Total 23 254 (81.5)
ADR=adverse drug reaction; ICD=International Classification of Diseases; NSAIDs=non-steroidal anti-
inflammatory drugs; ENT=ear, nose, throat.
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variablesthatreflectormeasure relativedisadvantage,
including low income, low educational attainment,
highunemployment,andlowskilledoccupation;ithas
been used extensively in public health research.
27 The
continuousvaluesoftheindexeswerethenpartitioned
into fifths.
Statistical analysis
Statistical analysis was performed with SPSS version
12.0.1 (SPSS, Chicago, IL). We used the independent
samples t test for continuous variables and a χ
2 test for
categorical variables to compare characteristics
between patients with first time only and repeat ADR
episodes. Variables associated with first time admis-
sions for an ADR were used for univariate and
multivariate analysis. Univariate analysis was under-
takentoscreenforpotentiallyimportantvariablestobe
used in the subsequent multivariate analysis. Multi-
variate Cox proportional hazards regression models
were fitted by using all variables included as main
effects terms, and we performed corresponding linear
trend tests. When assessing each drug category, we
fitted the Cox regression models using deviation
coding, which compared the effect on repeat ADRs
ofeachfirsttimedrugcategorywiththeaverageriskof
all 20 drug categories. We obtained hazard ratios and
associated 95% confidence intervals after adjusting for
age, sex, indigenous status, residential locality, socio-
economicdisadvantage,admissiontype,hospitaltype,
length of hospital stay, calendar period of ADR,
Charlson comorbidity index, and drug categories.
Other studies have identified these variables as those
influencing the risk of first time ADRs,
10-15 and they
were significant predictors of repeat ADRs based on
the preceding univariate analysis. To assess potential
for survival bias, we separately analysed data from all
patientsandfromasubsetthatexcludedthosewhodied
in the three year follow-up period.
RESULTS
Results using data from all patients were similar to
thoseobtainedwhenweexcludedpatientswhodiedin
thefollow-upperiod.Wehavethereforereportedonly
the results from analyses that included all patients.
Within the first three years of follow-up, 5056 patients
(17.7%) experienced a repeat admission for an ADR.
Table 4presentsunadjustedandadjustedhazardratios
for repeat ADRs for selected characteristics in the
participants. The adjusted hazard ratios for repeat
ADRswere1.08(95%confidenceinterval1.02to1.15)
for men, 0.87 (0.80 to 0.93) for private hospital
admissions, 1.11 (1.05 to 1.18) for length of hospital
stay≥14days,2.34(2.00to2.73)foradmissionin1995-
9comparedwiththeearliesttimeperiod,and1.71(1.46
to 1.99) for a Charlson comorbidity index score ≥7,
with a significant linear trend across quantitative or
ordinal quantitative variables. Residential location in
the metropolitan area (1.10, 1.01 to 1.19) was margin-
allysignificant(P=0.03).Therewasnosignificanteffect
on repeat ADRs for age, indigenous status, type of
admission, and socioeconomic disadvantage.
Table 5 shows the effects of individual Charlson
comorbidconditionsonrepeatADRs.Comparedwith
patients who had no recorded comorbidity, the
analysis identified sizeable adjusted hazard ratios for
congestive cardiac failure (1.56, 1.43 to 1.71), periph-
eral vascular disease (1.27, 1.09 to 1.48), chronic
pulmonary disease (1.61, 1.45 to 1.79), rheumatologi-
cal disease (1.65,1.41 to1.92), mild liver disease (1.48,
1.05 to 2.07), mild to moderate diabetes (1.18, 1.07 to
1.30), diabetes with chronic complications (1.91, 1.65
to 2.22), renal disease (1.93, 1.71 to 2.17), any
malignancy including lymphoma and leukaemia
(1.87, 1.68 to 2.09), moderate to severe liver disease
(1.85, 1.18 to 2.92), and metastatic solid tumour (2.25,
1.92 to 2.64). Cerebrovascular disease (0.85, 0.73 to
0.98), dementia (0.62, 0.49 to 0.78), and hemiplegia or
paraplegia (0.73, 0.59 to 0.89) were apparently
preventive for repeat ADRs. There was no significant
relationformyocardialinfarction,pepticulcerdisease,
or AIDS, although people with AIDS had only two
repeat ADRs.
Table 6 shows the effect of each drug category (as
defined in ICD-10-AM) responsible for first time
ADRs. Three drug categories were associated with a
greaterthanaverageriskofrepeatADRs,withadjusted
hazard ratios of 1.51 (1.34 to 1.69) for hormones, 2.12
(1.89 to 2.38) for primarily systemic agents (including
antineoplastics, immunosuppressives, and anti-
neoplastic antibiotics), and 4.06 (2.00 to 8.26) for
bacterial vaccines. The latter category, however, had
low counts for first time and repeat ADRs.
DISCUSSION
Predictive factors for repeat ADR admission
In this population based cohort study of factors that
predict repeat admission for ADRs in older adults we
Table 3 |Charlson comorbidity conditions (with weights) present at admission for first time
adverse drug reaction (ADR) in 28 548 patients aged ≥60, Western Australia, 1980-2000
Charlson comorbid conditions Weight No (%) of patients
Myocardial infarction 1 1556 (5.5)
Congestive cardiac failure 1 4745 (16.6)
Peripheral vascular disease 1 1174 (4.1)
Cerebrovascular disease 1 1827 (6.4)
Dementia 1 868 (3.0)
Chronic pulmonary disease 1 2034 (7.1)
Rheumatological disease 1 832 (2.9)
Peptic ulcer disease 1 2145 (7.5)
Mild liver disease 1 199 (0.7)
Diabetes (mild to moderate) 1 2807 (9.8)
Diabetes with complications 2 755 (2.6)
Hemiplegia or paraplegia 2 864 (3.0)
Renal disease 2 1418 (5.0)
Any malignancy, including lymphoma/leukaemia 2 3349 (11.7)
Moderate or severe liver disease 3 108 (0.4)
Metastatic solid tumour 6 1518 (5.3)
AIDS 6 5 (0.0)
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diseaseratherthanadvancingageincreasestheirrateof
repeat ADRs. Comorbid congestive cardiac failure,
diabetes, and peripheral vascular, chronic pulmonary,
rheumatological, hepatic, renal, and malignant dis-
eases were all strong predictors of readmissions for
ADRs.Ourresultswereconsistentwiththoseofearlier
studies that a higher Charlson comorbidity index
score,
4renalinsufficiency,
28anddiabetes
29wereallrisk
factors for first time ADRs. We also found that
comorbid cerebrovascular disease, dementia, and
hemiplegia or paraplegia were associated with a
Table 4 |Unadjusted and adjusted hazard ratios (with 95% confidence intervals) of repeat adverse drug reaction (ADRs) for
selected characteristics in older adults
Characteristics at first
admission for ADR
First time ADR
only (n=23 492)
Repeat ADR
(n=5056)
Unadjusted Adjusted
HR (95% CI) P value* HR (95% CI)† P value*
Age at admission (years):
60-64 3226 790 1.00‡
0.18
1.00‡
0.39
65-69 3830 870 0.96 (0.87 to 1.05) 0.97 (0.88 to 1.07)
70-74 4697 982 0.90 (0.82 to 0.99) 0.93 (0.84 to 1.02)
75-79 4647 1009 0.95 (0.86 to 1.04) 0.99 (0.91 to 1.10)
≥80 7092 1405 0.92 (0.84 to 1.00) 0.96 (0.87 to 1.05)
Sex:
Female 13 264 2810 1.00‡
<0.001
1.00‡
<0.01
Male 10 228 2246 1.13 (1.07 to 1.19) 1.08 (1.02 to 1.15)
Indigenous status:
Non-Aboriginal/TSI 23 288 5006 1.00‡
0.34
1.00‡
0.85
Aboriginal/TSI 204 50 1.15 (0.87 to 1.52) 1.03 (0.77 to 1.37)
Residential locality:
Regional/rural area 3936 847 1.00‡
0.53
1.00‡
0.03
Metropolitan Perth 19 556 4209 1.02 (0.95 to 1.10) 1.10 (1.01 to 1.19)
Admission type:
Elective 6469 1405 1.00‡
0.75
1.00‡
0.13
Emergency 17 007 3648 1.01 (0.95 to 1.07) 1.05 (0.99 to 1.12)
Type of hospital attended:
Public 19 542 4063 1.00‡
<0.001
1.00
<0.001 Private 3275 930 1.32 (1.23 to 1.42) 0.87 (0.80 to 0.93)
Other 675 63 0.41 (0.32 to 0.53) 0.80 (0.61 to 1.04)
Length of hospital stay (days):
<14 15 803 3408 1.00‡
<0.001
1.00‡
0.001
≥14 7689 1648 1.14 (1.08 to 1.21) 1.11 (1.05 to 1.18)
Socioeconomic disadvantage (fifths):
1 (most) 4671 982 1.00‡
<0.001
1.00‡
0.15
2 5495 1055 0.92 (0.85 to 1.01) 0.90 (0.83 to 0.99)
3 3184 710 1.05 (0.96 to 1.16) 0.99 (0.90 to 1.09)
4 3365 733 1.04 (0.95 to 1.15) 0.95 (0.86 to 1.04)
5 (least) 6752 1575 1.11 (1.02 to 1.20) 0.94 (0.87 to 1.02)
Calendar period of ADR:
1980-4 2097 183 1.00‡
<0.001
1.00‡
<0.001
1985-9 3540 459 1.48 (1.25 to 1.76) 1.44 (1.21 to 1.72)
1990-4 5915 780 1.53 (1.31 to 1.80) 1.52 (1.29 to 1.79)
1995-9 9409 1946 2.37 (2.03 to 2.75) 2.34 (2.00 to 2.73)
Charlson comorbidity index score:
0 9511 1719 1.00‡
<0.001
1.00‡
<0.001
1-2 10 220 2396 1.46 (1.38 to 1.56) 1.30 (1.22 to 1.38)
3-4 2262 579 1.86 (1.69 to 2.04) 1.42 (1.29 to 1.57)
5-6 563 151 2.82 (2.38 to 3.33) 2.04 (1.72 to 2.42)
≥7 936 211 3.10 (2.68 to 3.58) 1.71 (1.46 to 1.99)
TSI=Torres Strait Islander.
*Test for trend or standard P value across quantitative or ordinal quantitative variables.
†Estimates from Cox regression model included terms for age (continuous), sex (female, male), indigenous status (non-Aboriginal, Aboriginal),
residence (regional/rural area, metropolitan), admission type (elective, emergency), type of hospital attended (public, private, other), lengtho fs t a y
(continuous), socioeconomic disadvantage (fifths), calendar period of ADR (continuous), Charlson comorbidity index score (continuous), and drug
categories responsible for first time ADR.
‡Reference category.
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admission for an ADR with a longer hospital stay,
admissions in the most recent time period, and male
sex also predicted repeat ADR admissions, with
admission to private hospitals showing a reduced risk.
ADRs are acknowledged as a major health problem
in older people.
1-730 A meta-analysis of 68 observa-
tional studies reported that the proportion of admis-
sions related to ADRs in older people was four times
higher than in younger people.
31 We found, however,
thatadvancingagewasnotindependentlypredictiveof
repeatadmissionsrelatedtoADRsinpeople≥60.This
is consistent with results from previous studies that
have examined the independent effects of age on first
timeADRs.
1113Otherreportedriskfactorsforfirsttime
ADRs include sex, multiple drug regimens, inap-
propriate use of drugs, alcohol intake, cognitive
function, and depression.
410-15 To our knowledge,
however, the same risk factors for repeat ADRs have
not been previously investigated.
Strengths and limitations
There are several potential explanations for the
observed importance of comorbidity. Comorbidity
might increase vulnerability to ADRs by impairing
body systems—for example, cardiovascular, pulmon-
ary, renal, and hepatic insufficiency can cause changes
in pharmacokinetics and pharmacodynamics.
28 There
might be increased opportunity for drug interactions
because of polypharmacy for multiple morbidities.
Finally, Berkson’s bias—that is, ADRs are more likely
to be identified and diagnosed because of comorbid
conditionsincreasingaperson’scontactwiththehealth
system.
32 A reduced risk of repeat ADRs associated
with admission to private hospital might be explained
by private patients having generally better health or
being socioeconomically advantaged and having
stronger social supports. This latter theory, however,
is inconsistent with the direct measure of least socio-
economic disadvantage used in this study, which had
no effect (hazard ratio 0.94, 0.87 to 1.02).
Animportantlimitationofthestudywastheabsence
ofdatainthehospitalmorbiditydatasystemonspecific
drug doses and multiple drug regimens. Nevertheless,
we did have information on the drug category
primarilyresponsibleforADRs.Weassessedtheeffect
ofeachdrugcategorybycomparingitwiththeaverage
risk of a repeat ADR from the 20 drug categories
responsible for first time ADRs. Hormones, primarily
systemicagents,andbacterialvaccineswereassociated
withhigherthanaveragerisksofrepeatADR,although
the numbers in the bacterialvaccines group was small.
The higher risk of repeat ADRs from hormones and
primarily systemic agents (which include anti-
neoplastic drugs) was expected as severe side effects
of these drugs are well known. We examined the
diagnoses in patients who had first time ADRs caused
by bacterial vaccines and found that nearly 38% of
these patients had malignant diseases treated with
bacillus Calmette-Guerin (BCG) vaccine or other
vaccine based immunotherapy. Hence, the increased
effect on repeat ADRs observed in the category of
bacterial vaccines was probably caused by the con-
comitant use of antineoplastic agents (part of “primar-
ily systemic agents”). The age standardised rates of all
cancers for males and females in 2005 were 356.1 and
260.9per100000personyears,basedonapublication
from the Western Australia cancer registry.
33 Hence,
men have a higher incidence of cancer than women in
Western Australia, which might explain the observed
higher risk of repeat ADRs in men.
The risk of adverse drug effects might increase with
increasing drug dose. Although we did not have
specific data on drug dose for individuals in our
populationdataset,weinvestigatedtheextenttowhich
doses were prescribed within the normal limits set by
the manufacturers as documented in the Monthly
Index of Medical Specialities (MIMS-Australia), a
database containing approved product information
from manufacturers for medicines used in Australia.
34
Weobtaineddataonpharmacydispensingofdrugsfor
discharge and outpatients for the year 2000 from the
Table 5 |Adjusted hazard ratios (HR) with 95% confidence intervals for repeat adverse drug
reactions (ADRs) for Charlson comorbidity at first admission to hospital for ADR in older adults
Comorbid conditions
No (%) with first
time ADR only
No (%) with
repeat ADR
Adjusted HR
(95% CI)* P value†
Congestive cardiac failure 3858 (16.4) 889 (17.6) 1.56 (1.43 to
1.71)
<0.001
Peripheral vascular disease 978 (4.2) 196 (3.9) 1.27 (1.09 to
1.48)
<0.01
Chronic pulmonary disease 1537 (6.5) 497 (9.8) 1.61 (1.45 to
1.79)
<0.001
Rheumatological disease 622 (2.6) 210 (4.2) 1.65 (1.41 to
1.92)
<0.001
Mild liver disease 164 (0.7) 35 (0.7) 1.48 (1.05 to
2.07)
0.03
Diabetes (mild to moderate) 2276 (9.7) 531 (10.5) 1.18 (1.07 to
1.30)
<0.01
Diabetes with chronic complications 507 (2.2) 248 (4.9) 1.91 (1.65 to
2.22)
<0.001
Renal disease 1045 (4.4) 373 (7.4) 1.93 (1.71 to
2.17)
<0.001
Any malignancy including lymphoma
and leukaemia
2538 (10.8) 811 (16.0) 1.87 (1.68 to
2.09)
<0.001
Moderate or severe liver disease 89 (0.4) 19 (0.4) 1.85 (1.18 to
2.92)
<0.01
Metastatic solid tumour 1245 (5.3) 273 (5.4) 2.25 (1.92 to
2.64)
<0.001
Cerebrovascular disease 1601 (6.8) 226 (4.5) 0.85 (0.73 to
0.98)
0.02
Dementia 791 (3.4) 77 (1.5) 0.62 (0.49 to
0.78)
<0.001
Hemiplegia or paraplegia 762 (3.2) 102 (2.0) 0.73 (0.59 to
0.89)
<0.01
Myocardial infarction 1332 (5.7) 224 (4.4) 0.98 (0.84 to
1.13)
0.73
Peptic ulcer disease 1847 (7.9) 298 (5.9) 1.09 (0.95 to
1.25)
0.24
AIDS 3 (<0.1) 2 (<0.1) 1.65 (0.41 to
6.71)
0.48
*Estimates from Cox regression models included terms for age (continuous), sex (female, male), indigenous
status (non-Aboriginal, Aboriginal), residence (regional/rural area, metropolitan), admission type (elective,
emergency), type of hospital attended (public, private, other), length of stay (continuous), socioeconomic
disadvantage (fifths), calendar period of ADR (continuous), and drug categories responsible for first-time ADR.
†For hazard ratio (HR), using patients with absent comorbidity as reference category.
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in Western Australia. Analysis of prescribed doses for
these drugs showed that nearly all (99.6%) were within
the range recommended by the manufacturer as
recorded in MIMS Australia.
34
The strengths of our studyinclude the cohort design
with population based and audited data of high
quality,
17 thus overcoming issues related to selection
and recall biases as well as loss to follow-up. Loss to
follow-up would have been small as interstate migra-
tion occurred in only 3.5% of residents in Western
Australia during the 24 year study period.
35 The
longitudinal linked data allowed us to identify repeat
ADRs in the same patient regardless of changes in the
treating hospital. The fact that death records were
linkedto69%ofparticipantswasconsistentwithahigh
level of completeness of follow-up. An important
limitation of the study was that the administrative
hospital morbidity data system is known to code only
60%ofthe17Charlsoncomorbidconditionsrelativeto
information obtained from chart review.
23 False
positive diagnoses of comorbid conditions, however,
are infrequent for most conditions (range 0-1.5%).
23
Although underascertainment of comorbidity is an
issueinthisstudy,itseemsimplausiblethatthelevelsof
underascertainment would differ substantially
between patients with first time ADR only and those
with repeat ADRs. Another limitation was that the
studyfocusedonlyonADRsthateithercausedhospital
admission or extended hospital stay, whereas most
ADRs (90%) are fairly minor and occur in the
community without admission to hospital.
36 ADRs
resulting in admission, however, represent the most
severeadversesideeffectsofmedicationuseandleadto
considerable morbidity and financial costs. They are
thus arguably the most appropriate object of analysis.
As with other studies of this nature, reliability of
ascertainment might vary because the presence and
diagnosis of an ADR is subject to clinical judgment.
The diagnosis of an ADR was made by senior hospital
doctors (consultants and registrars) and junior doctors
recorded them in text on a structured hospital
separationabstract.Thisstepintheprocesswassubject
to diagnostic error at a level that is usual in clinical
practice. The second step in the process involved
codingthetext,includingexternalcausesorcontribut-
ing factors, using the ICD-9, ICD-9-CM, or ICD-10-
AM coding manuals (for different time periods). This
was performed in each of the hospitals by qualified
clinical coders who are trained in the use of the ICD
codes and were able to obtain additional information
from the medical notes as required. The accuracy of
Table 6 |Adjusted hazard ratios (with 95% confidence intervals) of repeat adverse drug reactions (ADRs) for primary drug
category responsible for first time ADRs in older adults
Drug category*
No (%) with
first time
ADR only No (%) with repeat ADR Adjusted HR (95% CI)† P value‡
E930/Y40 Systemic antibiotics§ 2249 (9.6) 423 (8.4) 0.81 (0.45 to 1.50) 0.53
E931/Y41 Other systemic anti-infectives/antiparasitics 365 (1.6) 65 (1.3) 1.02 (0.80 to 1.30) 0.89
E932/Y42Hormones(includingsyntheticandantagonists) 1649 (7.0) 525 (10.4) 1.51 (1.34 to 1.69) <0.001
E933/Y43 Primarily systemic agents 1456 (6.2) 666 (13.2) 2.12 (1.89 to 2.38) <0.001
E934/Y44 Agents primarily affecting blood constituents 1980 (8.4) 452 (8.9) 0.93 (0.82 to 1.05) 0.23
E935/Y45 Analgesics/antipyretics/anti-inflammatory
drugs
4006 (17.1) 688 (13.6) 0.76 (0.68 to 0.84) <0.001
E936/Y46 Antiepileptics/antiparkinsonian drugs 903 (3.8) 218 (4.3) 1.13 (0.97 to 1.32) 0.12
E937/Y47 Sedatives, hypnotics, antianxiety drugs 356 (1.5) 50 (1.0) 0.74 (0.56 to 0.97) 0.03
E938/Y48 Anaesthetics, therapeutic gases 372 (1.6) 42 (0.8) 0.52 (0.39 to 0.71) <0.001
E939/Y49 Psychotropic drugs§ 1266 (5.4) 268 (5.3) 0.96 (0.83 to 1.11) 0.56
E940/Y50 Central nervous system stimulants 15 (0.1) 3 (0.1) 0.76 (0.26 to 2.22) 0.61
E941/Y51 Drugs primarily affecting autonomic nervous
system§
377 (1.6) 99 (2.0) 0.87 (0.71 to 1.07) 0.18
E942/Y52Agentsprimarilyaffectingcardiovascularsystem 4702 (20.0) 874 (17.3) 0.93 (0.84 to 1.04) 0.21
E943/Y53 Agents primarily affecting gastrointestinal
system
220 (0.9) 32 (0.6) 0.64 (0.46 to 0.90) 0.01
E944/Y54 Agents affecting water balance/minerals/uric
acid metabolism§
1703 (7.2) 321 (6.4) 0.99 (0.86 to 1.13) 0.96
E945/Y55 Agents affecting muscle/respiratory system 490 (2.1) 73 (1.4) 1.01 (0.80 to 1.27) 0.96
E946/Y56 Topical agents affecting skin, ENT, dental 496 (2.1) 81 (1.6) 0.86 (0.69 to 1.07) 0.18
E947/Y57 Other and unspecified drugs and medicines 824 (3.5) 158 (3.1) 1.02 (0.86 to 1.21) 0.80
E948/Y58 Bacterial vaccines 9 (<0.1) 7 (0.1) 4.06 (2.00 to 8.26) <0.001
E949/Y59 Other and unspecified vaccines/biologicals 54 (0.2) 11 (0.2) 0.96 (0.54 to 1.69) 0.88
*See table 1 for more explicit specifications of ICD-9/ICD-9-CM and ICD-10-CM code definitions.
†Estimates from Cox regression model included terms for age (continuous), sex (female, male), indigenous status (non-Aboriginal, Aboriginal),
residence (regional/rural area, metropolitan), admission type (elective, emergency), type of hospital attended (public, private, other), lengtho fs t a y
(continuous), socioeconomic disadvantage (fifths), calendar period of ADR (continuous), and Charlson comorbidity index score (continuous).
‡P value for each drug category responsible for first time ADR compared with overall effect of drug categories.
§See table 1 for details of modification in drug category between coding systems.
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 7 of 9clinicalcoding(includingEcodes)isroutinelychecked
by coding supervisors as well as by random internal
audits.
We found that older adults who experienced an
ADRduringthemostrecentstudyperiod,1995-9,had
a 2.4-foldgreater risk of recurrencethan their counter-
partsin1980-4.Asthestudywaslongitudinal,weneed
to consider the influence of factors that changed with
time. The results are consistent with national drug
consumption data that showed an increase in drug
exposure in older Australians of 4.7% during 2000-1
alone.
37 This increase greatly exceeded population
growth,suggestingeitheralargerpopulationatriskora
higheraveragelevelofdrugexposureperpatient.Our
results,derivedfrompopulationleveldata,suggestthat
there exists a strong temporal correlation between
repeatADRsinolderadultsandgreateruseofdrugsin
thecommunitygenerally.
3038Whileeffortstoimprove
thecodingofADRsinhospitalmorbiditydatasystems
during the observation period might have contributed
tosomeoftheobservedriseinadmissionsforADRs,an
earliervalidationstudyinWesternAustralia,involving
a review of hospital charts, found a real increase in
hospital morbidity caused by ADRs from 1980 to
1991.
39
Conclusions
This population based cohort study found that
comorbidity and not advancing age predicted repeat
a d m i s s i o nf o rA D R si np a t i e n t sa g e do v e r6 0 .
Comorbid congestive cardiac failure, peripheral vas-
cular, chronic pulmonary, rheumatological, hepatic,
renal, and malignant diseases, and diabetes were the
comorbid conditions most likely to predict readmis-
sion for ADRs from the therapeutic use of drugs. An
apparent preventive effect was observed with comor-
bidcerebrovasculardisease,dementia,andhemiplegia
orparaplegia,possiblybecausesuchpatientsareunder
more consistent healthcare supervision. Careful and
frequentmonitoringofprescribeddrugsinolderadults
with at risk comorbidities might prevent readmissions
for ADRs. Evaluation of monitoring programmes
delivered by local pharmacists, community nurses,
and general practitioners might be the next step
towards prevention.
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